Two additional vaccines for Covid-19 may be authorized for use in the US in the coming months as the country tries to deal with record hospitalizations and deaths.
The COVID-19 vaccine developed by the University of Oxford and AstraZeneca wasn’t the first to be OK’d by regulators in the U.K.—health officials authorized the Pfizer-BioNTech jab nearly four weeks earlier. And it’s not the most effective—Stage 3 clinical trials suggest it prevents COVID-19 symptoms about 70% of the time vs. about 95% for the Pfizer vaccine and a similar one from Moderna (which is authorized in the U.S., but not the U.K.).
The first thing to know about the Oxford-AstraZeneca jab is that it’s cheap. AstraZeneca has promised it will not make a profit on the vaccine during the pandemic. As a result, it costs $3 to $4 per dose around the world. Compare that to $25 to $37 a dose for the vaccine developed by Moderna and about $20 a dose for Pfizer’s jab, according to figures reported in Europe.
The Oxford-AstraZeneca Covid-19 vaccine that the United Kingdom approved for use on Wednesday may be authorized for emergency use in the US in April, according to Moncef Slaoui, chief scientific adviser for Operation Warp Speed.
In addition, Johnson and Johnson’s single-dose vaccine may be authorized for emergency use in February and could be a “game changer” for the US, Slaoui said. Phase 3 trial recruitment for this vaccine has been completed.
Source for this information is CNN and Time magazine.
Coast Contact 